Search results for " Advanced"

showing 10 items of 173 documents

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to succ…

2019

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods:…

0301 basic medicineCancer ResearchReviewDiseasechemistry.chemical_compound0302 clinical medicineRibociclibMolecular Targeted TherapyAbemaciclibClinical Trials as TopicDisease ManagementMetastatic breast cancerEverolimuOncologyReceptors Estrogen030220 oncology & carcinogenesisFemaleAdvanced breast cancerReceptors ProgesteroneBreast Neoplasmmedicine.drugHumanmedicine.medical_specialtyNeutropeniaDrug-Related Side Effects and Adverse ReactionsAntineoplastic Agents HormonalProtein Kinase InhibitorBreast NeoplasmsPalbociclibPalbociclib03 medical and health sciencesBreast cancermedicineBiomarkers TumorHumansEverolimusIntensive care medicineAdverse effectProtein Kinase InhibitorsEverolimusbusiness.industrymedicine.diseaseClinical trialAbemaciclib030104 developmental biologychemistryMED/06 - ONCOLOGIA MEDICAbusinessDrug-Related Side Effects and Adverse ReactionAbemaciclib; Advanced breast cancer; Everolimus; Neutropenia; Palbociclib; Ribociclib
researchProduct

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer

2020

Simple Summary The outcome for patients with rectal cancer has significantly improved over the last thirty years. Previously, local relapses in the pelvis occurred in more than one third of all patients with apparently localized tumors. Total mesorectal excision was the first step to improve local control by reducing local relapses to less than 5%. Preoperative radiation, either short-course or long-course with concurrent administration of chemotherapy, was a second important step for reducing local relapses to a minimum, even in locally advanced tumors where a clean surgical resection was not possible or would not be curative. Magnetic resonance imaging is a very useful tool for locoregion…

0301 basic medicineCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentLocally advancedReviewlcsh:RC254-282law.inventionMetastasis03 medical and health sciencesMesorectal fascia0302 clinical medicineRandomized controlled triallawmedicinewatch and wait strategyChemotherapyPreoperative chemoradiotherapyPostoperative chemotherapybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-risk locally advanced rectal cancer; Total neoadjuvant treatment; Watch and wait strategyhigh-risk locally advanced rectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisRadiologybusinesstotal neoadjuvant treatmentCancers
researchProduct

Infrared microspectroscopic determination of collagen cross-links in articular cartilage

2017

Collagen forms an organized network in articular cartilage to give tensile stiffness to the tissue. Due to its long half-life, collagen is susceptible to cross-links caused by advanced glycation end-products. The current standard method for determination of cross-link concentrations in tissues is the destructive high-performance liquid chromatography (HPLC). The aim of this study was to analyze the cross-link concentrations nondestructively from standard unstained histological articular cartilage sections by using Fourier transform infrared (FTIR) microspectroscopy. Half of the bovine articular cartilage samples ( n = 27 ) were treated with threose to increase the collagen cross-linking whi…

0301 basic medicineCartilage ArticularGlycation End Products AdvancedcollagenSpectrophotometry InfraredPROTEOGLYCAN01 natural sciencesHigh-performance liquid chromatographychemistry.chemical_compoundBiomedicinsk laboratorievetenskap/teknologiPartial least squares regressionBiomedical Laboratory Science/Technologyinfrared spectroscopyPyridinolineThreoseChemistryMedicinsk bildbehandlingSTIFFNESSinfrapunaspektroskopiata3141AnatomyAtomic and Molecular Physics and OpticsDIFFUSIONElectronic Optical and Magnetic Materialsmedicine.anatomical_structuremultivariate analysisGLYCATION END-PRODUCTSNONENZYMATIC GLYCATIONBiomedical EngineeringInfrared spectroscopyI COLLAGENFORMALIN FIXATIONcross-linksOrthopaedicsBiomaterials03 medical and health sciencesmedicineAnimalsarticular cartilageFourier transform infrared spectroscopyPentosidineLeast-Squares Analysista217ChromatographyCartilage010401 analytical chemistry3126 Surgery anesthesiology intensive care radiology0104 chemical sciencesMedical Image Processing030104 developmental biologyOrtopedi1182 Biochemistry cell and molecular biologyCattleJournal of Biomedical Optics
researchProduct

Advanced Glycation End Products (AGEs): Biochemistry, Signaling, Analytical Methods, and Epigenetic Effects

2020

The advanced glycation end products (AGEs) are organic molecules formed in any living organisms with a great variety of structural and functional properties. They are considered organic markers of the glycation process. Due to their great heterogeneity, there is no specific test for their operational measurement. In this review, we have updated the most common chromatographic, colorimetric, spectroscopic, mass spectrometric, and serological methods, typically used for the determination of AGEs in biological samples. We have described their signaling and signal transduction mechanisms and cell epigenetic effects. Although mass spectrometric analysis is not widespread in the detection of AGEs…

0301 basic medicineChronic exposureGlycation End Products AdvancedAgingSpecific testComputational biologyReview ArticleBiochemistryOrganic moleculesEpigenesis Genetic03 medical and health sciences0302 clinical medicineGlycationAGE antioxidants epigenetics biochemistry.MedicineHumansEpigeneticsQH573-671business.industryCell BiologyGeneral MedicineMass spectrometricAutofluorescence030104 developmental biology030220 oncology & carcinogenesisbusinessCytologySignal TransductionOxidative Medicine and Cellular Longevity
researchProduct

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

2021

[Background and Aims] Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH).

0301 basic medicineFIBROSIS NONINVASIVE ASSESSMENTCirrhosisTransient elastographydeMILI0302 clinical medicineMedicineBARIATRIC SURGERY CANDIDATESNon-alcoholic steatohepatitismedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISFatty liverMagnetic Resonance Imaging3. Good healthArea Under CurveLiver biopsyElasticity Imaging TechniquesNASH-MRI030211 gastroenterology & hepatologyBio-markersRadiologyElastographyDiffusion-weighted imagingLife Sciences & BiomedicineAdultPREDICTS ADVANCED FIBROSISmedicine.medical_specialtyBiomarkers deMILI Diffusion-weighted imaging Magnetic resonance elastography NASH-MRI Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Shear wave elastography Transient elastography AdultArea Under Curve Elasticity Imaging Techniques Humans Magnetic Resonance Imaging Non-alcoholic Fatty Liver Disease ROC Curve fibro-MRI Iron-corrected T1 Liver fibrosisLiver fibrosisCONTROLLED ATTENUATION PARAMETERSTIFFNESS MEASUREMENT03 medical and health sciencesIron-corrected T1HumansFATTY LIVER-DISEASEScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryRADIATION FORCE IMPULSEMagnetic resonance imagingmedicine.diseaseCONTROLLED TRANSIENT ELASTOGRAPHYMagnetic resonance elastography030104 developmental biologyROC CurveMagnetic resonance elastographyShear wave elastographyXL PROBEHuman medicinefibro-MRISteatohepatitisbusinessTransient elastographyBiomarkersNon-alcoholic fatty liver diseaseJournal of Hepatology
researchProduct

Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.

2017

Diabetic microangiopathy, including retinopathy, is characterized by abnormal growth and leakage of small blood vessels, resulting in local edema and functional impairment of the depending tissues. Mechanisms leading to the impairment of microcirculation in diabetes are multiple and still largely unclear. However, a dysregulated vascular regeneration appears to play a key role. In addition, oxidative and hyperosmolar stress, as well as the activation of inflammatory pathways triggered by advanced glycation end-products and toll-like receptors, have been recognized as key underlying events. Here, we review recent knowledge on cellular and molecular pathways of microvascular disease in diabet…

0301 basic medicineGlycation End Products AdvancedPhysiologyDiabetes retinopathyGlycation End ProductsDiseaseFibroblast growth factorHMGB1DiabeteMicrocirculationCapillary Permeability03 medical and health sciencesGlycationDiabetes mellitusmedicineSettore MED/05 - Patologia ClinicaAnimalsHumansCellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy; Physiology; Molecular Medicine; PharmacologyNeovascularizationPharmacologyPathologicbiologyNeovascularization Pathologicbusiness.industryMicrocirculationMicroangiopathyDiabetesToll-Like Receptorsmedicine.diseasePrognosisCellular and molecular pathways; Diabetes; Diabetes retinopathy; Microangiopathy; Animals; Capillary Permeability; Diabetic Angiopathies; Glycation End Products Advanced; Humans; Inflammation Mediators; Microcirculation; Microvessels; Neovascularization Pathologic; Oxidative Stress; Prognosis; Signal Transduction; Toll-Like ReceptorsOxidative Stress030104 developmental biologyCellular and molecular pathwaysMicroangiopathyImmunologyMicrovesselsbiology.proteinMolecular MedicineAdvancedCellular and molecular pathwayInflammation MediatorsbusinessDiabetic AngiopathiesRetinopathySignal TransductionVascular pharmacology
researchProduct

A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following fi…

2016

4011Background: Pts with advanced gastric cancer have a poor prognosis with median overall survival (OS) of ~1 yr. Ipi is a monoclonal antibody that enhances T-cell activation and T-effector cell t...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyFirst linemedicine.medical_treatmentGastro esophageal junctionLocally advancedIpilimumab03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicineIn patientChemotherapybusiness.industryCancermedicine.diseaseSurgery030104 developmental biologyOncology030220 oncology & carcinogenesisOpen labelbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advance…

2016

TPS4134Background: Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers. Avelumab* is a fully human anti-PD-L1 ...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybiologybusiness.industryLocally advancedbiology.organism_classificationAvelumab03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncologyMaintenance therapyJavelin030220 oncology & carcinogenesisInternal medicinemedicineIn patientFirst line chemotherapyReceptorbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab…

2020

Abstract Background: Neoantigens arising from somatic mutations are attractive targets for cancer immunotherapy as they may be recognized as foreign by the immune system. RO7198457, a systemically administered RNA-Lipoplex iNeST was designed to stimulate T cell responses against neoantigens. A first-in-human Phase Ib study of RO7198457, in combination with the aPD-L1 antibody atezolizumab is being conducted in patients with locally advanced or metastatic solid tumors. Methods: RO7198457 is manufactured on a per-patient basis and contains up to 20 tumor-specific neoepitopes. Nine doses of RO7198457 were administered i.v. in weekly and bi-weekly intervals during the 12-week induction stage an…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMelanomaMedizinLocally advancedSpecific immunotherapyCancermedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCancer immunotherapyAtezolizumab030220 oncology & carcinogenesisInternal medicinemedicinePrior ImmunotherapyIn patientbusinessCancer Research
researchProduct

Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points

2018

0301 basic medicineOncologyDisease free survivalmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentLocally advancedMEDLINERectumRisk AssessmentDisease-Free Survival03 medical and health sciences0302 clinical medicineText miningInternal medicineHumansMedicineNeoadjuvant therapyRectal Neoplasmsbusiness.industryRectumHematologymedicine.diseaseNeoadjuvant Therapy030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbusinessRisk assessmentAnnals of Oncology
researchProduct